In 2014, Marshall et al. reported a lower frequency of known NPM1 and FLT3-ITD mutations in a South African AML cohort and suggested that race-specific mutations might contribute to AML pathogenesis and also to the lower frequency of detection of these mutations [14]. The gene discussed is FLT3; the disease is acute myeloid leukemia.